Terms: = Ovarian cancer AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4 AND Treatment
109 results:
1. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
[TBL] [Abstract] [Full Text] [Related]
2. Adjuvant ovarian Function Suppression in Premenopausal Hormone Receptor-Positive Breast cancer.
Basmadjian RB; Lupichuk S; Xu Y; Quan ML; Cheung WY; Brenner DR
JAMA Netw Open; 2024 Mar; 7(3):e242082. PubMed ID: 38477918
[TBL] [Abstract] [Full Text] [Related]
3. Nanoparticle Targeting in Chemo-Resistant ovarian cancer Reveals Dual Axis of Therapeutic Vulnerability Involving Cholesterol Uptake and Cell Redox Balance.
Wang Y; Calvert AE; Cardenas H; Rink JS; Nahotko D; Qiang W; Ndukwe CE; Chen F; Keathley R; Zhang Y; Cheng JX; Thaxton CS; Matei D
Adv Sci (Weinh); 2024 Apr; 11(13):e2305212. PubMed ID: 38263873
[TBL] [Abstract] [Full Text] [Related]
4. Fibroblast Growth Factor Receptors and Ligands in Context of Bevacizumab Response in ovarian Carcinoma: An Exploratory Analysis of AGO-OVAR11/ICON-7.
Heublein S; Pfisterer J; du Bois A; Anglesio M; Aminossadati B; Bhatti I; Sehouli J; Wimberger P; Schochter F; Hilpert F; Hillemanns P; Kalder M; Schroeder W; Mahner S; Burges A; Canzler U; Gropp-Meier M; Jackisch C; Harter P; Kommoss S; Marmé F
Lab Invest; 2024 Apr; 104(4):100321. PubMed ID: 38154497
[TBL] [Abstract] [Full Text] [Related]
5. A B7-H4-Targeting Antibody-Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant cancers with B7-H4 Expression.
Gitto SB; Whicker M; Davies G; Kumar S; Kinneer K; Xu H; Lewis A; Mamidi S; Medvedev S; Kim H; Anderton J; Tang EJ; Ferman B; Coats S; Wilkinson RW; Brown E; Powell DJ; Simpkins F
Clin Cancer Res; 2024 Apr; 30(8):1567-1581. PubMed ID: 37882675
[TBL] [Abstract] [Full Text] [Related]
6. Highly proliferative and hypodifferentiated CAR-T cells targeting B7-H3 enhance antitumor activity against ovarian and triple-negative breast cancers.
Zhang X; Guo H; Chen J; Xu C; Wang L; Ke Y; Gao Y; Zhang B; Zhu J
Cancer Lett; 2023 Sep; 572():216355. PubMed ID: 37597651
[TBL] [Abstract] [Full Text] [Related]
7. Targeting BRPF3 moderately reverses olaparib resistance in high grade serous ovarian carcinoma.
Bitler BG; Bailey CA; Yamamoto TM; McMellen A; Kim H; Watson ZL
Mol Carcinog; 2023 Nov; 62(11):1717-1730. PubMed ID: 37493106
[TBL] [Abstract] [Full Text] [Related]
8. Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the treatment of cancer.
Toader D; Fessler SP; Collins SD; Conlon PR; Bollu R; Catcott KC; Chin CN; Dirksen A; Du B; Duvall JR; Higgins S; Kozytska MV; Bellovoda K; Faircloth C; Lee D; Li F; Qin L; Routhier C; Shaw P; Stevenson CA; Wang J; Wongthida P; Ter-Ovanesyan E; Ditty E; Bradley SP; Xu L; Yin M; Yurkovetskiy AV; Mosher R; Damelin M; Lowinger TB
Mol Cancer Ther; 2023 Sep; 22(9):999-1012. PubMed ID: 37294948
[TBL] [Abstract] [Full Text] [Related]
9. Chimeric Antigen Receptor T-cell Therapy in cancer: A Critical Review.
Sharma R; Suravarjhula L; Banerjee M; Kumar G; Kumar N
Curr Drug Res Rev; 2023; 15(3):241-261. PubMed ID: 36825696
[TBL] [Abstract] [Full Text] [Related]
10. The stromal tumor-infiltrating lymphocytes, cancer stemness, epithelial-mesenchymal transition, and B7-H4 expression in ovarian serous carcinoma.
Hwang C; Lee HJ; Na JY; Kim KH; Song YJ; Kim JY; Kim K; Shin DH; Park JY; Kim SY; Lee JH; Choi KU
J Ovarian Res; 2023 Jan; 16(1):3. PubMed ID: 36609273
[TBL] [Abstract] [Full Text] [Related]
11. Dual roles of oxostephanine as an Aurora kinase inhibitor and angiogenesis suppressor.
Tran TT; Vu LB; Nguyen HQ; Pham HB; Do XT; Than UTT; Pham TT; Do LD; Le KT; Nguyen TP; Hoang MT
Int J Mol Med; 2022 Nov; 50(5):. PubMed ID: 36102296
[TBL] [Abstract] [Full Text] [Related]
12. CpG-binding protein CFP1 promotes ovarian cancer cell proliferation by regulating BST2 transcription.
Yang LQ; Hu HY; Han Y; Tang ZY; Gao J; Zhou QY; Liu YX; Chen HS; Xu TN; Ao L; Xu Y; Che X; Jiang YB; Xu CW; Zhang XC; Jiang YX; Heger M; Wang XM; Cheng SQ; Pan WW
Cancer Gene Ther; 2022 Dec; 29(12):1895-1907. PubMed ID: 35864225
[TBL] [Abstract] [Full Text] [Related]
13. Histone deacetylase inhibitor, panobinostat, exerts anti-proliferative effect with partial normalization from aberrant epigenetic states on granulosa cell tumor cell lines.
Hazama Y; Tsujioka T; Kitanaka A; Tohyama K; Shimoya K
PLoS One; 2022; 17(7):e0271245. PubMed ID: 35802681
[TBL] [Abstract] [Full Text] [Related]
14. Anti-Extra Domain B Splice Variant of Fibronectin Antibody-Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade.
Hooper AT; Marquette K; Chang CB; Golas J; Jain S; Lam MH; Guffroy M; Leal M; Falahatpisheh H; Mathur D; Chen T; Kelleher K; Khandke K; Muszynska E; Loganzo F; Rosfjord E; Lucas J; Kan Z; Subramanyam C; O'Donnell C; Neri D; Gerber HP; May C; Sapra P
Mol Cancer Ther; 2022 Sep; 21(9):1462-1472. PubMed ID: 35793468
[TBL] [Abstract] [Full Text] [Related]
15. Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience.
Gerratana L; Movarek M; Wehbe F; Katam N; Mahalingam D; Donahue J; Shah A; Chae YK; Mulcahy M; Tsarwhas D; Villaflor V; Kalyan A; Hussein M; Patel J; Chandra S; Platanias LC; Gradishar W; Cristofanilli M; Behdad A
JCO Precis Oncol; 2022 Jun; 6():e2100289. PubMed ID: 35772051
[TBL] [Abstract] [Full Text] [Related]
16. Genome-scale CRISPR-Cas9 screen reveals novel regulators of B7-H3 in tumor cells.
Zhao S; Wang Y; Yang N; Mu M; Wu Z; Li H; Tang X; Zhong K; Zhang Z; Huang C; Cao T; Zheng M; Wang G; Nie C; Yang H; Guo G; Zhou L; Zheng X; Tong A
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35768165
[TBL] [Abstract] [Full Text] [Related]
17. Expression pattern and prognostic potential of histamine receptors in epithelial ovarian cancer.
Kraus FBT; Topalov NE; Deuster E; Hysenaj I; Mayr D; Chelariu-Raicu A; Beyer S; Kolben T; Burges A; Mahner S; Trillsch F; Jeschke U; Czogalla B
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2501-2511. PubMed ID: 35751684
[TBL] [Abstract] [Full Text] [Related]
18. Senotherapy Protects against Cisplatin-Induced ovarian Injury by Removing Senescent Cells and Alleviating DNA Damage.
Du D; Tang X; Li Y; Gao Y; Chen R; Chen Q; Wen J; Wu T; Zhang Y; Lu H; Zhang J; Wang S
Oxid Med Cell Longev; 2022; 2022():9144644. PubMed ID: 35693700
[TBL] [Abstract] [Full Text] [Related]
19. TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in ovarian cancer.
Lecker LSM; Berlato C; Maniati E; Delaine-Smith R; Pearce OMT; Heath O; Nichols SJ; Trevisan C; Novak M; McDermott J; Brenton JD; Cutillas PR; Rajeeve V; Hennino A; Drapkin R; Loessner D; Balkwill FR
Cancer Res; 2021 Nov; 81(22):5706-5719. PubMed ID: 34561272
[TBL] [Abstract] [Full Text] [Related]
20. Soluble B7-H3 in ovarian cancer and Its Predictive Value.
Kovaleva OV; Belova TP; Korotkova EA; Kushlinskii DN; Gratchev AN; Petrikova NA; Kudlay DA; Kushlinskii NE
Bull Exp Biol Med; 2021 Aug; 171(4):472-474. PubMed ID: 34542756
[TBL] [Abstract] [Full Text] [Related]
[Next]
